Format

Send to

Choose Destination
Lancet HIV. 2019 Nov;6(11):e788-e799. doi: 10.1016/S2352-3018(19)30238-3. Epub 2019 Sep 23.

Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline.

Author information

1
National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
2
UCLA Center for Clinical AIDS Research and Education, University of California, Los Angeles, Los Angeles, CA, USA.
3
National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Electronic address: gbeatriz@ini.fiocruz.br.

Abstract

Pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine was adopted by WHO as a strategy to reduce HIV incidence. Although shown to be highly effective in reducing HIV acquisition, the protective efficacy of oral tenofovir disoproxil fumarate and emtricitabine relies on optimal adherence, which poses a challenge for a key portion of the most at-risk populations (women, young individuals [15-24 years], racial and ethnic minority men who have sex with men, and transgender women). New PrEP agents in clinical development include novel oral agents (eg, tenofovir alafenamide and islatravir [also known as MK-8591]), long-acting injectables (eg, cabotegravir), vaginal rings, broadly neutralising monoclonal antibodies, topical products (including gels, films, and enemas), and multipurpose technologies. In addition, new drug delivery systems, such as implants and transdermal devices, are promising strategies that are being developed for HIV prevention. The ultimate goal of this new PrEP research agenda is to expand the available PrEP regimens and offer preventive technologies that will appeal to a wide variety of individuals with different needs over the course of their sexually active lifespan.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center